Overview

This second volume of Strategic Patent and Commercialization Journey of Nemonoxacin examines the molecule's progression through the most consequential stages of its development. Moving from late-phase clinical evaluation to regulatory negotiation, manufacturing scale-up, and early post-approval deployment, the narrative situates Nemonoxacin within the broader scientific and policy environment shaping antimicrobial innovation. Central to this account is TaiGen's systematic construction of a durable intellectual property and life-cycle management strategy. Through data-driven patent generation, jurisdiction-specific protection plans, and targeted extensions of clinical and formulation claims, the company sought to secure long-term market viability in a competitive therapeutic domain. Set against shifting regional politics and Taiwan's growing biotech ambitions, this volume offers a close, unvarnished look at how a medicine survives the long arc from development to market - and how a company uses every lever available, from clinical evidence to life-cycle management, to keep that arc intact. For readers interested in the human and strategic story behind drug development, it is both a case study and a record of a pivotal moment in Taiwan's scientific history.

Full Product Details

9781971588223

Table of Contents

Reviews

Author Information

Tab Content 6

Countries Available